Table 1.

Patient demographics

No relapse (25)Relapse (22)Statistical significance
Age (years, median)54 (37–67)53 (22–76)NS
Stage0.0295
 I8 (32%)2 (9%)
 II15 (60%)12 (55%)
 III2 (8%)8 (36%)
Tumor size0.0029
 T111 (44%)3 (14%)
 T212 (48%)10 (45%)
 T31 (4%)3 (14%)
 T41 (4%)5 (23%)
 TX01 (4%)
Nodes0.0394
 Yes10 (40%; N1:4, N2:2, N3:4)16 (73%; N1:11, N2:3, N3:2)
 No15 (60%)6 (27%)
GradeNS
 25 (20%)5 (23%)
 320 (80%)17 (77%)
Adjuvant chemotherapyNS
 Anthracycline-based chemotherapy19 (76%)13 (59%)
 Other chemotherapy4 (16%; 2 carboplatin based)4 (18%; 1 carboplatin based)
 No adjuvant chemotherapy2 (8%)5 (23%)
SurgeryNS
 Conservative13 (52%)7 (32%)
 Mastectomy12 (48%)15 (68%)
RadiotherapyNS
 Yes13 (52%)11 (50%)
 No12 (48%)11 (50%)
Time to relapse (months, median)N/A18.5 months (8 to 97)
Disease-free survival (months, median)96 months (25 to 137)N/A
RaceNS
 White14 (56%)15 (68%)
 African American10 (40%)6 (28%)
 Unknown1 (4%)1 (4%)
Breast cancer subtypeNS
 BL19 (76%)19 (86%)
 Others6 (24%)3 (14%)
  • Abbreviations: N/A, not applicable; NS, not statistically significant.